Accelerating sensory recovery after sciatic nerve crush: non-selective versus melanocortin MC4 receptor-selective peptides

Melanocortin receptor ligands accelerate functional recovery after peripheral nerve crush. It is not known which mechanism is involved or via which melanocortin receptor this effect occurs, albeit indirect evidence favours the melanocortin MC4 receptor. To test whether the melanocortin MC4 receptor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2004-07, Vol.495 (2-3), p.145-152
Hauptverfasser: NIJENHUIS, Wouter A. J, WANDERS, Nienke, KRUIJTZER, John A. W, LISKAMP, Rob M, GISPEN, Willem Hendrik, ADAN, Roger A. H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 152
container_issue 2-3
container_start_page 145
container_title European journal of pharmacology
container_volume 495
creator NIJENHUIS, Wouter A. J
WANDERS, Nienke
KRUIJTZER, John A. W
LISKAMP, Rob M
GISPEN, Willem Hendrik
ADAN, Roger A. H
description Melanocortin receptor ligands accelerate functional recovery after peripheral nerve crush. It is not known which mechanism is involved or via which melanocortin receptor this effect occurs, albeit indirect evidence favours the melanocortin MC4 receptor. To test whether the melanocortin MC4 receptor is involved in the effects of melanocortins on functional recovery, we used melanocortin compounds that distinguish the melanocortin MC4 receptor from the melanocortin MC1, MC3 and MC5 receptors on basis of selectivity and agonist/antagonist profile. Activation and binding studies indicated that the previously described peptides JK1 (Ac-Nle-Gly-Lys-D-Phe-Arg-Trp-Gly-NH2) and [D-Tyr4]melanotan-II ([D-Tyr4]MTII. Ac-Nle-c[Asp-His-D-Tyr-Arg-Trp-Lys]NH2) are selective for the rat melanocortin MC4 receptor as compared to the rat melanocortin MC3 and MC5 receptors, but are also potent on the melanocortin MC1 receptor. Both peptides did not accelerate sensory recovery in rats with a sciatic nerve crush, whereas the non-selective melanocortin agonist melanotan-II (MTII, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]NH2) was effective. The melanocortin MC3/MC4 receptor antagonist SHU9119 (Ac-Nle-c[Asp-His-D-Nal(2)-Arg-Trp-Lys]NH2) also enhanced sensory recovery. This effect was probably not due to interaction with the melanocortin MC4 receptor, since JK46 (Ac-Gly-Lys-His-D-Nal(2)-Arg-Trp-Gly-NH2), a selective melanocortin MC4 receptor antagonist, was ineffective. Taken together, these data suggest that melanocortins do not accelerate sensory recovery via interaction with the melanocortin MC4 receptor. From the known melanocortin receptors, only the involvement of the melanocortin MC5 receptor in acceleration of recovery could not be excluded.
doi_str_mv 10.1016/j.ejphar.2004.05.037
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66700806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66700806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-7d0886cfa38ad75ff78b7da06c1804872a1a4e65b08ba64d27828e52c5b9a0ab3</originalsourceid><addsrcrecordid>eNpNkE1P3DAQhq2qqGxp_0FV5VJuCWPHX-GGVvRDAnGBs-U4k5LVbpx6EiT49Xi7K8HJ1vh5X40fxr5xqDhwfbGpcDM9-lQJAFmBqqA2H9iKW9OUYLj4yFYAXJaiaZpT9ploAwCqEeoTO-VKyIbresVerkLALSY_D-PfgnCkmJ6LhCE-Yb74fsZUUBjyeyhGTE9YhLTQ42UxxrGkHA3zkIeZpoWKHW79GENMua64Xct9E05zTO_QKQ-GDukLO-n9lvDr8TxjDz-v79e_y5u7X3_WVzdlqOt6Lk0H1urQ-9r6zqi-N7Y1nQcduAVpjfDcS9SqBdt6LTthrLCoRFBt48G39Rk7P_ROKf5bkGa3Gyh_Om-KcSGntQGwoDMoD2BIkShh76Y07Hx6dhzc3rnbuINzt3fuQLnsPMe-H_uXdofdW-goOQM_joCn4Ld98mMY6B3XyP_gK44vj0o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66700806</pqid></control><display><type>article</type><title>Accelerating sensory recovery after sciatic nerve crush: non-selective versus melanocortin MC4 receptor-selective peptides</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>NIJENHUIS, Wouter A. J ; WANDERS, Nienke ; KRUIJTZER, John A. W ; LISKAMP, Rob M ; GISPEN, Willem Hendrik ; ADAN, Roger A. H</creator><creatorcontrib>NIJENHUIS, Wouter A. J ; WANDERS, Nienke ; KRUIJTZER, John A. W ; LISKAMP, Rob M ; GISPEN, Willem Hendrik ; ADAN, Roger A. H</creatorcontrib><description>Melanocortin receptor ligands accelerate functional recovery after peripheral nerve crush. It is not known which mechanism is involved or via which melanocortin receptor this effect occurs, albeit indirect evidence favours the melanocortin MC4 receptor. To test whether the melanocortin MC4 receptor is involved in the effects of melanocortins on functional recovery, we used melanocortin compounds that distinguish the melanocortin MC4 receptor from the melanocortin MC1, MC3 and MC5 receptors on basis of selectivity and agonist/antagonist profile. Activation and binding studies indicated that the previously described peptides JK1 (Ac-Nle-Gly-Lys-D-Phe-Arg-Trp-Gly-NH2) and [D-Tyr4]melanotan-II ([D-Tyr4]MTII. Ac-Nle-c[Asp-His-D-Tyr-Arg-Trp-Lys]NH2) are selective for the rat melanocortin MC4 receptor as compared to the rat melanocortin MC3 and MC5 receptors, but are also potent on the melanocortin MC1 receptor. Both peptides did not accelerate sensory recovery in rats with a sciatic nerve crush, whereas the non-selective melanocortin agonist melanotan-II (MTII, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]NH2) was effective. The melanocortin MC3/MC4 receptor antagonist SHU9119 (Ac-Nle-c[Asp-His-D-Nal(2)-Arg-Trp-Lys]NH2) also enhanced sensory recovery. This effect was probably not due to interaction with the melanocortin MC4 receptor, since JK46 (Ac-Gly-Lys-His-D-Nal(2)-Arg-Trp-Gly-NH2), a selective melanocortin MC4 receptor antagonist, was ineffective. Taken together, these data suggest that melanocortins do not accelerate sensory recovery via interaction with the melanocortin MC4 receptor. From the known melanocortin receptors, only the involvement of the melanocortin MC5 receptor in acceleration of recovery could not be excluded.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2004.05.037</identifier><identifier>PMID: 15249163</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier</publisher><subject>alpha-MSH - pharmacology ; Animals ; Biological and medical sciences ; Cell Line ; Dose-Response Relationship, Drug ; Humans ; Male ; Medical sciences ; Melanocyte-Stimulating Hormones - pharmacology ; Oligopeptides - pharmacology ; Pharmacology. Drug treatments ; Plasmids - genetics ; Rats ; Rats, Wistar ; Receptor, Melanocortin, Type 4 - agonists ; Receptor, Melanocortin, Type 4 - genetics ; Receptor, Melanocortin, Type 4 - physiology ; Receptors, Melanocortin - genetics ; Receptors, Melanocortin - physiology ; Recovery of Function - drug effects ; Recovery of Function - physiology ; Sciatic Nerve - injuries ; Sciatic Nerve - physiopathology ; Sensory Thresholds ; Time Factors ; Transfection</subject><ispartof>European journal of pharmacology, 2004-07, Vol.495 (2-3), p.145-152</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c333t-7d0886cfa38ad75ff78b7da06c1804872a1a4e65b08ba64d27828e52c5b9a0ab3</citedby><cites>FETCH-LOGICAL-c333t-7d0886cfa38ad75ff78b7da06c1804872a1a4e65b08ba64d27828e52c5b9a0ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15944916$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15249163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NIJENHUIS, Wouter A. J</creatorcontrib><creatorcontrib>WANDERS, Nienke</creatorcontrib><creatorcontrib>KRUIJTZER, John A. W</creatorcontrib><creatorcontrib>LISKAMP, Rob M</creatorcontrib><creatorcontrib>GISPEN, Willem Hendrik</creatorcontrib><creatorcontrib>ADAN, Roger A. H</creatorcontrib><title>Accelerating sensory recovery after sciatic nerve crush: non-selective versus melanocortin MC4 receptor-selective peptides</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Melanocortin receptor ligands accelerate functional recovery after peripheral nerve crush. It is not known which mechanism is involved or via which melanocortin receptor this effect occurs, albeit indirect evidence favours the melanocortin MC4 receptor. To test whether the melanocortin MC4 receptor is involved in the effects of melanocortins on functional recovery, we used melanocortin compounds that distinguish the melanocortin MC4 receptor from the melanocortin MC1, MC3 and MC5 receptors on basis of selectivity and agonist/antagonist profile. Activation and binding studies indicated that the previously described peptides JK1 (Ac-Nle-Gly-Lys-D-Phe-Arg-Trp-Gly-NH2) and [D-Tyr4]melanotan-II ([D-Tyr4]MTII. Ac-Nle-c[Asp-His-D-Tyr-Arg-Trp-Lys]NH2) are selective for the rat melanocortin MC4 receptor as compared to the rat melanocortin MC3 and MC5 receptors, but are also potent on the melanocortin MC1 receptor. Both peptides did not accelerate sensory recovery in rats with a sciatic nerve crush, whereas the non-selective melanocortin agonist melanotan-II (MTII, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]NH2) was effective. The melanocortin MC3/MC4 receptor antagonist SHU9119 (Ac-Nle-c[Asp-His-D-Nal(2)-Arg-Trp-Lys]NH2) also enhanced sensory recovery. This effect was probably not due to interaction with the melanocortin MC4 receptor, since JK46 (Ac-Gly-Lys-His-D-Nal(2)-Arg-Trp-Gly-NH2), a selective melanocortin MC4 receptor antagonist, was ineffective. Taken together, these data suggest that melanocortins do not accelerate sensory recovery via interaction with the melanocortin MC4 receptor. From the known melanocortin receptors, only the involvement of the melanocortin MC5 receptor in acceleration of recovery could not be excluded.</description><subject>alpha-MSH - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Dose-Response Relationship, Drug</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanocyte-Stimulating Hormones - pharmacology</subject><subject>Oligopeptides - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasmids - genetics</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptor, Melanocortin, Type 4 - agonists</subject><subject>Receptor, Melanocortin, Type 4 - genetics</subject><subject>Receptor, Melanocortin, Type 4 - physiology</subject><subject>Receptors, Melanocortin - genetics</subject><subject>Receptors, Melanocortin - physiology</subject><subject>Recovery of Function - drug effects</subject><subject>Recovery of Function - physiology</subject><subject>Sciatic Nerve - injuries</subject><subject>Sciatic Nerve - physiopathology</subject><subject>Sensory Thresholds</subject><subject>Time Factors</subject><subject>Transfection</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE1P3DAQhq2qqGxp_0FV5VJuCWPHX-GGVvRDAnGBs-U4k5LVbpx6EiT49Xi7K8HJ1vh5X40fxr5xqDhwfbGpcDM9-lQJAFmBqqA2H9iKW9OUYLj4yFYAXJaiaZpT9ploAwCqEeoTO-VKyIbresVerkLALSY_D-PfgnCkmJ6LhCE-Yb74fsZUUBjyeyhGTE9YhLTQ42UxxrGkHA3zkIeZpoWKHW79GENMua64Xct9E05zTO_QKQ-GDukLO-n9lvDr8TxjDz-v79e_y5u7X3_WVzdlqOt6Lk0H1urQ-9r6zqi-N7Y1nQcduAVpjfDcS9SqBdt6LTthrLCoRFBt48G39Rk7P_ROKf5bkGa3Gyh_Om-KcSGntQGwoDMoD2BIkShh76Y07Hx6dhzc3rnbuINzt3fuQLnsPMe-H_uXdofdW-goOQM_joCn4Ld98mMY6B3XyP_gK44vj0o</recordid><startdate>20040714</startdate><enddate>20040714</enddate><creator>NIJENHUIS, Wouter A. J</creator><creator>WANDERS, Nienke</creator><creator>KRUIJTZER, John A. W</creator><creator>LISKAMP, Rob M</creator><creator>GISPEN, Willem Hendrik</creator><creator>ADAN, Roger A. H</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040714</creationdate><title>Accelerating sensory recovery after sciatic nerve crush: non-selective versus melanocortin MC4 receptor-selective peptides</title><author>NIJENHUIS, Wouter A. J ; WANDERS, Nienke ; KRUIJTZER, John A. W ; LISKAMP, Rob M ; GISPEN, Willem Hendrik ; ADAN, Roger A. H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-7d0886cfa38ad75ff78b7da06c1804872a1a4e65b08ba64d27828e52c5b9a0ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>alpha-MSH - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Dose-Response Relationship, Drug</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanocyte-Stimulating Hormones - pharmacology</topic><topic>Oligopeptides - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasmids - genetics</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptor, Melanocortin, Type 4 - agonists</topic><topic>Receptor, Melanocortin, Type 4 - genetics</topic><topic>Receptor, Melanocortin, Type 4 - physiology</topic><topic>Receptors, Melanocortin - genetics</topic><topic>Receptors, Melanocortin - physiology</topic><topic>Recovery of Function - drug effects</topic><topic>Recovery of Function - physiology</topic><topic>Sciatic Nerve - injuries</topic><topic>Sciatic Nerve - physiopathology</topic><topic>Sensory Thresholds</topic><topic>Time Factors</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NIJENHUIS, Wouter A. J</creatorcontrib><creatorcontrib>WANDERS, Nienke</creatorcontrib><creatorcontrib>KRUIJTZER, John A. W</creatorcontrib><creatorcontrib>LISKAMP, Rob M</creatorcontrib><creatorcontrib>GISPEN, Willem Hendrik</creatorcontrib><creatorcontrib>ADAN, Roger A. H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NIJENHUIS, Wouter A. J</au><au>WANDERS, Nienke</au><au>KRUIJTZER, John A. W</au><au>LISKAMP, Rob M</au><au>GISPEN, Willem Hendrik</au><au>ADAN, Roger A. H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accelerating sensory recovery after sciatic nerve crush: non-selective versus melanocortin MC4 receptor-selective peptides</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2004-07-14</date><risdate>2004</risdate><volume>495</volume><issue>2-3</issue><spage>145</spage><epage>152</epage><pages>145-152</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Melanocortin receptor ligands accelerate functional recovery after peripheral nerve crush. It is not known which mechanism is involved or via which melanocortin receptor this effect occurs, albeit indirect evidence favours the melanocortin MC4 receptor. To test whether the melanocortin MC4 receptor is involved in the effects of melanocortins on functional recovery, we used melanocortin compounds that distinguish the melanocortin MC4 receptor from the melanocortin MC1, MC3 and MC5 receptors on basis of selectivity and agonist/antagonist profile. Activation and binding studies indicated that the previously described peptides JK1 (Ac-Nle-Gly-Lys-D-Phe-Arg-Trp-Gly-NH2) and [D-Tyr4]melanotan-II ([D-Tyr4]MTII. Ac-Nle-c[Asp-His-D-Tyr-Arg-Trp-Lys]NH2) are selective for the rat melanocortin MC4 receptor as compared to the rat melanocortin MC3 and MC5 receptors, but are also potent on the melanocortin MC1 receptor. Both peptides did not accelerate sensory recovery in rats with a sciatic nerve crush, whereas the non-selective melanocortin agonist melanotan-II (MTII, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]NH2) was effective. The melanocortin MC3/MC4 receptor antagonist SHU9119 (Ac-Nle-c[Asp-His-D-Nal(2)-Arg-Trp-Lys]NH2) also enhanced sensory recovery. This effect was probably not due to interaction with the melanocortin MC4 receptor, since JK46 (Ac-Gly-Lys-His-D-Nal(2)-Arg-Trp-Gly-NH2), a selective melanocortin MC4 receptor antagonist, was ineffective. Taken together, these data suggest that melanocortins do not accelerate sensory recovery via interaction with the melanocortin MC4 receptor. From the known melanocortin receptors, only the involvement of the melanocortin MC5 receptor in acceleration of recovery could not be excluded.</abstract><cop>Amsterdam</cop><pub>Elsevier</pub><pmid>15249163</pmid><doi>10.1016/j.ejphar.2004.05.037</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2004-07, Vol.495 (2-3), p.145-152
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_66700806
source MEDLINE; Elsevier ScienceDirect Journals
subjects alpha-MSH - pharmacology
Animals
Biological and medical sciences
Cell Line
Dose-Response Relationship, Drug
Humans
Male
Medical sciences
Melanocyte-Stimulating Hormones - pharmacology
Oligopeptides - pharmacology
Pharmacology. Drug treatments
Plasmids - genetics
Rats
Rats, Wistar
Receptor, Melanocortin, Type 4 - agonists
Receptor, Melanocortin, Type 4 - genetics
Receptor, Melanocortin, Type 4 - physiology
Receptors, Melanocortin - genetics
Receptors, Melanocortin - physiology
Recovery of Function - drug effects
Recovery of Function - physiology
Sciatic Nerve - injuries
Sciatic Nerve - physiopathology
Sensory Thresholds
Time Factors
Transfection
title Accelerating sensory recovery after sciatic nerve crush: non-selective versus melanocortin MC4 receptor-selective peptides
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T05%3A14%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accelerating%20sensory%20recovery%20after%20sciatic%20nerve%20crush:%20non-selective%20versus%20melanocortin%20MC4%20receptor-selective%20peptides&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=NIJENHUIS,%20Wouter%20A.%20J&rft.date=2004-07-14&rft.volume=495&rft.issue=2-3&rft.spage=145&rft.epage=152&rft.pages=145-152&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/j.ejphar.2004.05.037&rft_dat=%3Cproquest_cross%3E66700806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66700806&rft_id=info:pmid/15249163&rfr_iscdi=true